 | |
| Clinical data | |
|---|---|
| Other names | SENS-111; SENS111; UR-63325; UR63325 |
| Routes of administration | Oral[1] |
| Drug class | HistamineH4 receptorantagonist |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H21N5 |
| Molar mass | 235.335 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Seliforant (also known asSENS-111 orUR-63325) is aninvestigationalsmall-moleculedrug developed by Sensorion (originally by Palau Pharma) forinner-ear/vestibular disorders, particularlyvertigo andvestibular neuritis, and has also been cited as having potential fortinnitus andhearing loss indications.[2]
Seliforant was first developed as a first-in-classantagonist of thehistamine H4 receptor (H4R), areceptor subtype implicated in immune modulation and potentially neurosensory signalling.[1]
The drug was granted itsInternational Non-Proprietary Name (INN) "seliforant" by theWorld Health Organization in 2018.[2]
Seliforant functions byantagonising thehistamineH4 receptor (H4R).[1] H4 receptors are expressed in severaltissues includingimmune cells and may play roles inneurosensory signalling. The rationale for vestibular/ear indications is based on modulation of aberrant vestibular/inner-ear neuronal activity rather than conventionalantihistamine pathways.[3]
A Phase 2 proof-of-concept trial (NCT03110458 / EudraCT 2016–003927–45) of seliforant in acute unilateralvestibulopathy was completed, but seliforant did not meet its primary efficacy endpoint.[4]
Earlier Phase 2a trials in healthy volunteers assessingtolerability andpharmacodynamics reported that seliforant met tolerability endpoints (no sedation fromanticholinergic effects) but efficacy in patients remains unsupported.[5]
In human Phase 1/2 volunteer studies, seliforant was reported to be well tolerated, with mild to moderate events and nosedation reported.[5]